D. Ho

发表

Antigenic variation in gp120s from molecular clones of HIV-1 LAI.

J. Sodroski, J. Moore, H. Yoshiyama, 1993, AIDS research and human retroviruses.

Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120

C. Barbas, Q. Sattentau, J. Moore, 1995, Journal of virology.

HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy.

A. Trkola, J. Moore, D. Ho, 1999, The Journal of clinical investigation.

Dramatic Rise in Plasma Viremia after CD8+ T Cell Depletion in Simian Immunodeficiency Virus–infected Macaques

L. Weinberger, A. Perelson, J. Mittler, 1999, The Journal of experimental medicine.

Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome

D. Ho, Y. Cao, J. Safrit, 1994, Journal of virology.

Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection.

B. Walker, D. Ho, Y. Cao, 1996, AIDS research and human retroviruses.

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

A. Perelson, D. Ho, M. Markowitz, 1995, Nature.

HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time

A. Perelson, D. Ho, M. Markowitz, 1996, Science.

Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection.

D. Ho, Y. Cao, L. Zhang, 1995, The New England journal of medicine.

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

D. Ho, M. Markowitz, J. Leonard, 1996, Nature Medicine.

Identification of microRNAs of the herpesvirus family

C. Sander, D. Ho, M. Zavolan, 2005, Nature Methods.

Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy.

Ruy M Ribeiro, Alan S Perelson, A. Perelson, 2004, Mathematical biosciences.

Estimating average cellular turnover from 5–bromo–2'–deoxyuridine (BrdU) measurements

Alan S. Perelson, A. Perelson, D. Ho, 2003, Proceedings of the Royal Society of London. Series B: Biological Sciences.

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

A. Perelson, B. Korber, D. Ho, 1999, The New England journal of medicine.

Decay characteristics of HIV-1-infected compartments during combination therapy

Alan S. Perelson, A. Perelson, D. Ho, 1997, Nature.

Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation

Maxim N. Artyomov, Michael S. Seaman, Herman N. Eisen, 2010, Nature.

A Novel Antiviral Intervention Results in More Accurate Assessment of Human Immunodeficiency Virus Type 1 Replication Dynamics and T-Cell Decay In Vivo

Alan S. Perelson, A. Perelson, D. Ho, 2003, Journal of Virology.

Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor

D. Ho, M. Markowitz, H. Mo, 1997, Antimicrobial agents and chemotherapy.

Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.

M A Nowak, M. Nowak, D. Ho, 1998, Science.

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

Ron Diskin, Beatrix Ueberheide, Michael S. Seaman, 2011, Science.

Anti-CD4 Monoclonal Antibody Ibalizumab Exhibits Breadth and Potency Against HIV-1, With Natural Resistance Mediated by the Loss of a V5 Glycan in Envelope

D. Ho, M. Seaman, C. Pace, 2013, Journal of acquired immune deficiency syndromes.

Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite

D. Ho, Yicheng Guo, J. Yu, 2021, bioRxiv.

Potent Neutralizing Antibodies Directed to Multiple Epitopes on SARS-CoV-2 Spike

J. Sodroski, D. Ho, J. Chan, 2020, bioRxiv.

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

J. Sodroski, D. Ho, J. Chan, 2020, Nature.

A pH-dependent switch mediates conformational masking of SARS-CoV-2 spike

Tongqing Zhou, Baoshan Zhang, Richard A. Friesner, 2020, bioRxiv : the preprint server for biology.

Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections

B. Korber, D. Ho, J. Mascola, 2018, PLoS pathogens.

Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 B'/C Candidate Vaccine

D. Ho, Zhiwei Chen, A. Hurley, 2010, PloS one.

Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease

D. Ho, M. Markowitz, H. Mo, 1996, Antimicrobial agents and chemotherapy.

Time to hit HIV, early and hard.

D. Ho, D D Ho, 1995, The New England journal of medicine.

HIV-1 dynamics in vivo.

D. Ho, D D Ho, 1995, Journal of biological regulators and homeostatic agents.

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

R Brookmeyer, R. Siliciano, J. Margolick, 1997, Science.

Pathogenesis of infection with human immunodeficiency virus.

D. Ho, R. Pomerantz, D D Ho, 1987, The New England journal of medicine.

Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry

D. Ho, Zhiwei Chen, P. Marx, 1997, Journal of virology.

Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies

D. Ho, Neal N. Padte, M. Seaman, 2016, Journal of acquired immune deficiency syndromes.

Recombinant gp 120 Subunit Vaccines Virus Type 1 while Participating in Trials of Persons Infected by Human Immunodeficiency Immunological and Virological Analyses of

A. Trkola, B. Walker, B. Korber, 1998 .

Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines

A. Trkola, B. Walker, B. Korber, 1998, Journal of Virology.

Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1

D. Ho, J. Yu, D. Oren, 2013, Proceedings of the National Academy of Sciences.

The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapy

A. Perelson, J. Percus, D. Ho, 2003, Bulletin of mathematical biology.

Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression

D. Ho, R. Connor, 1994, Journal of virology.

Natural Mutations in the Receptor Binding Domain of Spike Glycoprotein Determine the Reactivity of Cross-Neutralization between Palm Civet Coronavirus and Severe Acute Respiratory Syndrome Coronavirus

D. Ho, Zhiwei Chen, Linqi Zhang, 2007, Journal of Virology.

Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1-neutralizing activity

D. Ho, D. Oren, M. Seaman, 2013, Nature Biotechnology.

The changing face of HIV in China

Li Yang, D. Ho, Linqi Zhang, 2008, Nature.

Macromolecular assemblage in the design of a synthetic AIDS vaccine.

D. Ho, B. Nardelli, J. Tam, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Campylobacter enteritis: early diagnosis with Gram's stain.

D. Ho, G. Murata, M. Ault, 1982, Archives of internal medicine.

Age‐dependent changes in T cell homeostasis and SIV load in sooty mangabeys

D. Ho, C. Cheng‐Mayer, S. Lewin, 2000, Journal of medical primatology.

Immunogenicity and protective efficacy of Clostridium difficile spore proteins.

D. Ho, Xingmin Sun, Adrianne N. Edwards, 2016, Anaerobe.

Dynamics of Intermittent Viremia during Highly Active Antiretroviral Therapy in Patients Who Initiate Therapy during Chronic versus Acute and Early Human Immunodeficiency Virus Type 1 Infection

A. Perelson, D. Ho, D. Follmann, 2004, Journal of Virology.

Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus

D. Ho, Zhiwei Chen, Linqi Zhang, 2007, Applied Microbiology and Biotechnology.

Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization.

M. Gurney, D. Ho, J. Kaplan, 1988, Science.

Sequence diversity of V1 and V2 domains of gp120 from human immunodeficiency virus type 1: lack of correlation with viral phenotype

D. Ho, T. Zhu, N. Wang, 1995, Journal of virology.

SARS-CoV-2 Transmission Risk Among National Basketball Association Players, Staff, and Vendors Exposed to Individuals With Positive Test Results After COVID-19 Recovery During the 2020 Regular and Postseason.

D. Ho, Y. Grad, D. Anderson, 2021, JAMA internal medicine.

Title Phase I safety and immunogenicity evaluation of ADVAX , aMultigenic , DNA-based Clade C / B ' HIV-1 candidate vaccine

D. Ho, Zhiwei Chen, A. Hurley, 2010 .

Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity

Seo Jung Hong, D. Ho, B. Stockwell, 2021, Journal of virology.

Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class

D. Ho, Yicheng Guo, J. Yu, 2021, bioRxiv.

A simplified cell-based assay to identify coronavirus 3CL protease inhibitors

Seo Jung Hong, D. Ho, B. Stockwell, 2020, bioRxiv.

SARS-CoV-2 Infected Cardiomyocytes Recruit Monocytes by Secreting CCL2

A. Borczuk, D. Ho, R. Schwartz, 2020, Research square.

SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus

P. Woo, D. Ho, Kwok-Hung Chan, 2005, Vaccine.

HIV-1 and influenza antigens synthetically linked to IgG2a Fc elicit superior humoral responses compared to unmodified antigens in mice.

D. Ho, J. Yu, G. Zaharatos, 2011, Vaccine.

Heterologous Expression and Purification of SARS-CoV2 Nucleocapsid Protein

D. Ho, L. Joshua-Tor, Lihong Liu, 2020, BIO-PROTOCOL.

A Replicating Modified Vaccinia Tiantan Strain Expressing an Avian-Derived Influenza H5N1 Hemagglutinin Induce Broadly Neutralizing Antibodies and Cross-Clade Protective Immunity in Mice

D. Ho, Zhiwei Chen, K. Yuen, 2013, PloS one.

A Glycolipid Adjuvant, 7DW8-5, Enhances CD8+ T Cell Responses Induced by an Adenovirus-Vectored Malaria Vaccine in Non-Human Primates

D. Ho, Chi‐Huey Wong, A. Gettie, 2013, PloS one.

HIV and lymphocyte dynamics.

D. Ho, 2002, Vaccine.

In Vivo Distribution of the Human Immunodeficiency Virus/Simian Immunodeficiency Virus Coreceptors: CXCR4, CCR3, and CCR5

D. Ho, Linqi Zhang, A. Talal, 1998, Journal of Virology.

An Isolate of Human Immunodeficiency Virus Type 1 Originally Classified as Subtype I Represents a Complex Mosaic Comprising Three Different Group M Subtypes (A, G, and I)

David L. Robertson, Martine Peeters, George M. Shaw, 1998, Journal of Virology.

Improving Mycobacterium bovis Bacillus Calmette-Guèrin as a Vaccine Delivery Vector for Viral Antigens by Incorporation of Glycolipid Activators of NKT Cells

B. Haynes, D. Ho, G. Besra, 2014, PloS one.

Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization

D. Ho, J. Yu, L. Shapiro, 2021, bioRxiv.

Induction of anti‐HIV neutralizing antibodies by synthetic peptides.

G. Linette, D. Ho, R. Kennedy, 1986, The EMBO journal.

Angiotensin converting enzyme 2 is a novel target of the γ-secretase complex

D. Ho, U. Pajvani, Pengfei Wang, 2021, Scientific Reports.

Angiotensin converting enzyme 2 is a novel target of the γ-secretase complex

D. Ho, U. Pajvani, Pengfei Wang, 2020, bioRxiv.

A third COVID-19 vaccine shot markedly boosts neutralizing antibody potency and breadth

D. Ho, H. Mohri, Y. Huang, 2021, medRxiv.

Emergence and Expansion of the SARS-CoV-2 Variant B.1.526 Identified in New York

D. Ho, Z. Sheng, H. Mohri, 2021, medRxiv.

Safety and Immunogenicity of ALVAC vCP1452 and Recombinant gp160 in Newly Human Immunodeﬁciency Virus Type 1-Infected Patients Treated with Prolonged Highly Active Antiretroviral Therapy

D. Ho, J. Binley, X. Jin, 2002 .

Transmission and pathogenesis of human immunodeficiency virus type 1.

D. Ho, R. Connor, 1994, AIDS research and human retroviruses.

Rapid generation of sequence variation during primary HIV‐1 infection

D. Ho, E. Daar, T. Moudgil, 1992, AIDS.

Distinction of human immunodeficiency virus type 1 neutralization and infection enhancement by human monoclonal antibodies to glycoprotein 120.

N. Haigwood, D. Ho, J. Robinson, 1992, The Journal of clinical investigation.

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

D. Ho, J. Mascola, Yicheng Guo, 2021, bioRxiv.

Genetic Characterization ofvif, vpr,andvpuSequences from Long-Term Survivors of Human Immunodeficiency Virus Type 1 Infection

D. Ho, S. Tuttleton, Linqi Zhang, 1997 .

Safety, pharmacokinetics, and antiviral activity of A77003, a C2 symmetry-based human immunodeficiency virus protease inhibitor

D. Ho, J. Leonard, A. Hsu, 1995, Antimicrobial agents and chemotherapy.

Natural Infection of a Homozygous (cid:68) 24 CCR5 Red-capped Mangabey with an R2b-Tropic Simian Immunodeﬁciency Virus

D. Ho, Zhiwei Chen, P. Marx, 1998 .

Human immunodeficiency virus type 1 strains of subtypes B and E replicate in cutaneous dendritic cell-T-cell mixtures without displaying subtype-specific tropism

A. Trkola, J. Moore, D. Ho, 1997, Journal of virology.

Bilateral Bell's palsy at the time of HIV seroconversion

D. Ho, Adam F. Wechselr, 1989, Neurology.

Isolation of HTLV-III from CSF and neural tissues of patients with AIDS-related neurological syndromes

R. Schooley, D. Ho, L. Resnick, 1987 .

Dendrite cell-T cell mixtures, isolated from the skin and mucosae of macaques, support the replication of SIV.

D. Ho, P. Marx, M. Pope, 1997, AIDS research and human retroviruses.

Risk of nosocomial infection with human T-cell lymphotropic virus III (HTLV-III).

R. Schooley, M. Hirsch, D. Ho, 1985, The New England journal of medicine.

Infection of human endothelial cells by human T-lymphotropic virus type I.

M. Hirsch, D. Ho, Rota Tr, 1984, Proceedings of the National Academy of Sciences of the United States of America.

Acute viral encephalitis.

M. Hirsch, D. Ho, David D. Ho, 1985, The Medical clinics of North America.

Replication of human cytomegalovirus in endothelial cells.

M. Hirsch, D. Ho, C. Andrews, 1984, The Journal of infectious diseases.

Toll-Like Receptor 5-Dependent Immunogenicity and Protective Efficacy of a Recombinant Fusion Protein Vaccine Containing the Nontoxic Domains of Clostridium difficile Toxins A and B and Salmonella enterica Serovar Typhimurium Flagellin in a Mouse Model of Clostridium difficile Disease

D. Ho, J. Yu, C. Kelly, 2013, Infection and Immunity.

Colocalization of a CD1d-Binding Glycolipid with a Radiation-Attenuated Sporozoite Vaccine in Lymph Node–Resident Dendritic Cells for a Robust Adjuvant Effect

Min Zhang, D. Ho, Chi‐Huey Wong, 2015, The Journal of Immunology.

Cerebral granulomatous angiitis associated with isolation of human T‐lymphotropic virus type III from the central nervous system

D. Ho, R. Sobel, B. Yankner, 1986, Annals of neurology.

Human T-cell lymphotropic virus type III (HTLV-III) core antigens: synthesis in Escherichia coli and immunoreactivity with human sera.

D. Ho, J. Ghrayeb, P. Chanda, 1986, DNA.

Epitope Mapping of Ibalizumab, a Humanized Anti-CD4 Monoclonal Antibody with Anti-HIV-1 Activity in Infected Patients

D. Ho, D. Franco, Chia-Ying Kao, 2010, Journal of Virology.

Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251

D. Ho, M. Markowitz, A. Gettie, 2017, AIDS.

Virus burden in human immunodeficiency virus type 1-infected children: relationship to disease status and effect of antiviral therapy.

D. Ho, N. Chelyapov, P. Brunell, 1991, Pediatrics.

Therapy of HIV infections: problems and prospects.

D. Ho, 1996, Bulletin of the New York Academy of Medicine.

Emergence and Expansion of the SARS-CoV-2 Variant B.1.526 Identified in New York

D. Ho, T. Bedford, Z. Sheng, 2021, medRxiv.

Multiple-site DNA vaccination enhances immune responses in mice.

D. Ho, Zhiwei Chen, Yaoxing Huang, 2006, Vaccine.

Prolonged severe acute respiratory syndrome coronavirus 2 persistence, attenuated immunologic response, and viral evolution in a solid organ transplant patient

D. Ho, M. Yin, H. Mohri, 2021, American Journal of Transplantation.

CD4-independent, productive infection of a neuronal cell line by human immunodeficiency virus type 1

D. Ho, H. Vinters, T. Moudgil, 1990, Journal of virology.

Pathogenesis of human immunodeficiency virus infection and prospects for control.

D. Ho, J. Kaplan, 1987, The Yale journal of biology and medicine.

Recognition of bacterial glycosphingolipids by natural killer T cells

D. Ho, Chi‐Huey Wong, Gisen Kim, 2005, Nature.

Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant

D. Ho, Chi‐Huey Wong, S. Vasan, 2010, Proceedings of the National Academy of Sciences.

Rational Design and Characterization of the Novel, Broad and Potent Bispecific HIV-1 Neutralizing Antibody iMabm36

D. Ho, Neal N. Padte, M. Seaman, 2014, Journal of acquired immune deficiency syndromes.

Prevention of Mother-to-Child Transmission of HIV-1 Using Highly Active Antiretroviral Therapy in Rural Yunnan, China

D. Ho, E. Geng, Qingling Chen, 2010, Journal of acquired immune deficiency syndromes.

Extrapulmonary manifestations of COVID-19

H. Krumholz, D. Ho, G. Stone, 2020, Nature Medicine.

Adaptive Evolution of Human Immunodeficiency Virus-Type 1 During the Natural Course of Infection

Steven M. Wolinsky, Michael Daniels, Manohar R. Furtado, 1996, Science.

Isolation and Quantitation of HIV in Peripheral Blood

D. Ho, A. Fauci, R. Koup, 1993, Current protocols in immunology.

Transmission of HIV by blood transfusion.

D. Ho, P. Francioli, S. Kleinman, 1988, The New England journal of medicine.

HIV/AIDS epidemiology, pathogenesis, prevention, and treatment

D. Ho, V. Simon, Viviana Simon, 2006, The Lancet.

Subacute encephalomyelitis of AIDS and its relation to HTLV‐III infection

R. Schooley, M. Hirsch, D. Ho, 1987, Neurology.

Modeling plasma virus concentration during primary HIV infection.

A S Perelson, A. Perelson, D. Ho, 2000, Journal of theoretical biology.

Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain

D. Ho, Yicheng Guo, Z. Sheng, 2021, bioRxiv.

Paired heavy and light chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses

Paul J. Steiner, Timothy A. Whitehead, D. Ho, 2020, bioRxiv.

Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains

R. Friesner, D. Ho, J. Mascola, 2020, Cell Host & Microbe.

HIV-1 dynamics in vivo: implications for therapy

D. Ho, V. Simon, David D. Ho, 2003, Nature Reviews Microbiology.

V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1

D. Ho, M. Nussenzweig, A. Moreau, 2016, Journal of acquired immune deficiency syndromes.

Intra-blood-brain-barrier synthesis of HTLV-III-specific IgG in patients with neurologic symptoms associated with AIDS or AIDS-related complex.

D. Ho, L. Resnick, W. Tourtellotte, 1985, The New England journal of medicine.

Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome.

R. Schooley, M. Hirsch, D. Ho, 1985, The New England journal of medicine.

Identification of the DC-SIGN-interactive domains on the envelope glycoprotein of HIV-1 CRF07_BC.

D. Ho, Yi‐Ming Arthur Chen, Sheng-Fan Wang, 2011, AIDS research and human retroviruses.

Identification of Drugs Blocking SARS-CoV-2 Infection using Human Pluripotent Stem Cell-derived Colonic Organoids

D. Ho, R. Schwartz, Dong-Li Xu, 2020, bioRxiv.

Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection.

D. Ho, E. Daar, D D Ho, 1991, The New England journal of medicine.

The role of a mutant CCR5 allele in HIV–1 transmission and disease progression

Steven M. Wolinsky, J. Phair, D. Ho, 1996, Nature Medicine.

A Polymorphism in the Regulatory Region of the CC-Chemokine Receptor 5 Gene Influences Perinatal Transmission of Human Immunodeficiency Virus Type 1 to African-American Infants

B. Korber, J. Moore, D. Ho, 1999, Journal of Virology.

Natural Infection of a Homozygous Δ24 CCR5 Red-capped Mangabey with an R2b-Tropic Simian Immunodeficiency Virus

D. Ho, Zhiwei Chen, P. Marx, 1998, The Journal of experimental medicine.

A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation

J. Phair, D. Ho, John P. Moore, 1998, Nature Medicine.

Streptococcal lymphadenitis in homosexual men with chronic lymphadenopathy.

D. Ho, G. Murata, 1984, The American journal of medicine.

Possible viral interactions in the acquired immunodeficiency syndrome (AIDS).

R. Schooley, M. Hirsch, D. Ho, 1984, Reviews of infectious diseases.

Endophthalmitis caused by the coagulase-negative staphylococci. 1. Disease spectrum and outcome.

D. Ho, J. Weiter, S. Buzney, 1993, Ophthalmology.

Primary human T-lymphotropic virus type III infection.

M. Hirsch, D. Ho, L. Resnick, 1985, Annals of internal medicine.

Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies

D. Ho, S. Kissler, Y. Grad, 2020, PLoS biology.

Molecular Characterization of Human Immunodeficiency Virus Type 1 and Hepatitis C Virus in Paid Blood Donors and Injection Drug Users in China

D. Ho, Zhiwei Chen, Linqi Zhang, 2004, Journal of Virology.

Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission

D. Ho, D. Cooper, Tuofu Zhu, 1996, Journal of virology.

Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques

A I Spira, D. Ho, Steven Wolinsky, 1996, The Journal of experimental medicine.

Genotypic and phenotypic characterization of HIV-1 patients with primary infection.

D. Ho, Y. Cao, R. Koup, 1993, Science.

High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.

D. Ho, E. Daar, T. Moudgil, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Quantitation of human immunodeficiency virus type 1 in the blood of infected persons.

D. Ho, D D Ho, T Moudgil, 1989, The New England journal of medicine.

Risk of Nosocomial Infection with Human T-Cell Lymphotropic Virus III (HTLV-III)

R. Schooley, M. Hirsch, D. Ho, 1985 .

Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes

D. Ho, J. Mascola, N. Sullivan, 2020, bioRxiv.

Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans

J. Moore, D. Ho, John P. Moore, 1993, Journal of virology.

Virus-Like Particle Based Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide

D. Ho, J. Mascola, J. Yu, 2020, Vaccines.

An Antigenic Threshold for Maintaining Human Immunodeficiency Virus Type 1-specific Cytotoxic T Lymphocytes

D. Ho, D. Nixon, S. Bonhoeffer, 2000, Molecular medicine.

A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A.

D. Ho, D. Franco, D. Gardiner, 2009, Vaccine.

Human Immunodeficiency Virus Type 1 Induces Persistent Changes in Mucosal and Blood γδ T Cells despite Suppressive Therapy

D. Ho, A. Hurley, M. Markowitz, 2003, Journal of Virology.

Immunohistochemical identification of HTLV‐III antigen in brains of patients with AIDS

M. Hirsch, D. Ho, R. Sobel, 1986, Annals of neurology.

Host-specific driving force in human immunodeficiency virus type 1 evolution in vivo

M P Busch, D. Ho, L. Zhang, 1997, Journal of virology.

Maternal HIV-1 viral load and vertical transmission of infection: The Ariel Project for the prevention of HIV transmission from mother to infant

C. Macken, B. Korber, D. Ho, 1997, Nature Medicine.

A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids

Duc-Huy T. Nguyen, A. Borczuk, D. Ho, 2020, Cell Stem Cell.

VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA

D. Ho, Yicheng Guo, P. Bieniasz, 2020, Cell host & microbe.

An African HIV-1 sequence from 1959 and implications for the origin of the epidemic

B. Korber, D. Ho, P. Sharp, 1998, Nature.

Measuring Recent Thymic Emigrants in Blood of Normal and HIV-1–Infected Individuals before and after Effective Therapy

Paul Palumbo, D. Ho, Steven Wolinsky, 1999, The Journal of experimental medicine.

Modeling COVID-19 with Human Pluripotent Stem Cell-Derived Cells Reveals Synergistic Effects of Anti-inflammatory Macrophages with ACE2 Inhibition Against SARS-CoV-2

D. Ho, R. Schwartz, H. Tse, 2020, Research square.

The Liver Is a Major Organ for Clearing Simian Immunodeficiency Virus in Rhesus Monkeys

Peter J. Dailey, D. Ho, A. Gettie, 2002, Journal of Virology.

Rapid Clearance of Simian Immunodeficiency Virus Particles from Plasma of Rhesus Macaques

Alan S. Perelson, Sebastian Bonhoeffer, Peter J. Dailey, 1999, Journal of Virology.

Plasma of Rhesus Macaques Immunodeficiency Virus Particles from Rapid Clearance of Simian

A. Perelson, D. Ho, A. Gettie, 1998 .

Ritonavir and saquinavir combination therapy for the treatment of HIV infection.

R Rode, M Salgo, D. Ho, 1999, AIDS.

Anti-idiotype monoclonal antibody elicits broadly neutralizing anti-gp120 antibodies in monkeys.

H. Yoshiyama, D. Ho, W. Morrow, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Correlation of perinatal transmission of human immunodeficiency virus type 1 with maternal viremia and lymphocyte phenotypes.

D. Ho, Y. Cao, W. Borkowsky, 1994, The Journal of pediatrics.

Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activity.

D. Ho, Chi‐Huey Wong, M. Tsuji, 2006, Journal of the American Chemical Society.

Synthesis and human NKT cell stimulating properties of 3-O-sulfo-α/β-galactosylceramides

D. Ho, Chi‐Huey Wong, M. Tsuji, 2005 .

Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.

D. Ho, Zhiwei Chen, Xiangming Li, 2008, Vaccine.

Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells.

D. Ho, Chi‐Huey Wong, M. Kronenberg, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes

B. Korber, J. Moore, D. Ho, 1996, Journal of virology.

CD4-independent, productive human immunodeficiency virus type 1 infection of hepatoma cell lines in vitro

D. Ho, Y. Cao, T. Moudgil, 1990, Journal of virology.

Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques

D. Ho, Gregory D. Gromowski, M. Diamond, 2021, bioRxiv.

Synthesis and human NKT cell stimulating properties of 3-O-sulfo-alpha/beta-galactosylceramides.

D. Ho, Chi‐Huey Wong, M. Tsuji, 2005, Bioorganic & medicinal chemistry.

A consensus–hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses

D. Ho, Chi‐Huey Wong, J. Jan, 2008, Proceedings of the National Academy of Sciences.

Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis

Sebastian Bonhoeffer, Alan S Perelson, John E Mittler, 1999, The Lancet.

A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection.

D. Ho, A. Hurley, M. Markowitz, 1998, The Journal of infectious diseases.

A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge

D. Ho, C. Cheng‐Mayer, M. Markowitz, 2015, Science Translational Medicine.

Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus

D. Ho, C. Cheng‐Mayer, M. Markowitz, 2014, Science.

Dominance of HIV-1 Subtype CRF01_AE in Sexually Acquired Cases Leads to a New Epidemic in Yunnan Province of China

D. Ho, Zhiwei Chen, Linqi Zhang, 2006, PLoS medicine.

Infection of monocyte/macrophages by human T lymphotropic virus type III.

M. Hirsch, D. Ho, D D Ho, 1986, The Journal of clinical investigation.

Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma.

D. Ho, Y. Cao, J. Lifson, 1995, AIDS research and human retroviruses.

Progesterone implants enhance SIV vaginal transmission and early virus load

D. Ho, A. Gettie, A. Lackner, 1996, Nature Medicine.

Human immunodeficiency virus type 2 (HIV-2) seroprevalence and characterization of a distinct HIV-2 genetic subtype from the natural range of simian immunodeficiency virus-infected sooty mangabeys

D. Ho, L. Zhang, A. Gettie, 1997, Journal of virology.

Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology

H Hui, D. Ho, F. Gao, 1994, Journal of virology.

Identification of SARS-CoV-2 Inhibitors using Lung and Colonic Organoids

Jared L. Johnson, Duc-Huy T. Nguyen, A. Borczuk, 2020, Nature.

Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations.

D. Ho, S. Lewin, Linqi Zhang, 2002, Blood.

Natural Variation in Vif: Differential Impact on APOBEC3G/3F and a Potential Role in HIV-1 Diversification

D. Ho, P. Bieniasz, V. Simon, 2005, PLoS pathogens.

Identification of Candidate COVID-19 Therapeutics using hPSC-derived Lung Organoids

Jared L. Johnson, Duc-Huy T. Nguyen, D. Ho, 2020, bioRxiv.

Genetic and Functional Diversity of Human Immunodeficiency Virus Type 1 Subtype B Nef Primary Isolates

D. Ho, V. Arora, J. Garcia, 2001, Journal of Virology.

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

D. Ho, J. Mascola, Yicheng Guo, 2021, Nature.

Dual Pathways of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trafficking Modulate the Selective Exclusion of Uncleaved Oligomers from Virions

Shijian Zhang, H. Ding, J. Kappes, 2020, Journal of Virology.

Determining the relative efficacy of highly active antiretroviral therapy.

Christine Hogan, Alan S Perelson, A. Perelson, 2003, The Journal of infectious diseases.

Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity

Jian Yu, Michael S. Seaman, D. Ho, 2016, Cell.

Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design

B. Haynes, D. Ho, J. Mascola, 2016, Journal of Virology.

Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions

J. Sodroski, D. Ho, J. Robinson, 1993, Journal of virology.

Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding

J. Sodroski, J. Moore, D. Ho, 1993, Journal of virology.

Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein

J. Sodroski, D. Ho, J. Robinson, 1992, Journal of virology.

Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals

D. Ho, Y. Cao, H. Mohri, 1993, Journal of virology.

An Immuno-Cardiac Model for Macrophage-Mediated Inflammation in COVID-19 Hearts

A. Borczuk, D. Ho, R. Schwartz, 2021, Circulation research.

CD40L-Containing Virus-Like Particle as a Candidate HIV-1 Vaccine Targeting Dendritic Cells

D. Ho, B. Hahn, Weimin Liu, 2011, Journal of acquired immune deficiency syndromes.

Normal T-Cell Turnover in Sooty Mangabeys Harboring Active Simian Immunodeficiency Virus Infection

D. Ho, C. Cheng‐Mayer, S. Lewin, 2000, Journal of Virology.

Design, Construction, and Characterization of a Dual-Promoter Multigenic DNA Vaccine Directed Against an HIV-1 Subtype C/B′ Recombinant

D. Ho, Zhiwei Chen, Yaoxing Huang, 2008, Journal of acquired immune deficiency syndromes.

Use of Real-Time PCR and Molecular Beacons To Detect Virus Replication in Human Immunodeficiency Virus Type 1-Infected Individuals on Prolonged Effective Antiretroviral Therapy

D. Ho, L. Zhang, A. Hurley, 1999, Journal of Virology.

Human immunodeficiency virus type-1 mRNA splicing pattern in infected persons is determined by the proportion of newly infected cells.

D. Ho, Y. Cao, M. Markowitz, 1997, Virology.

A Recoding Method to Improve the Humoral Immune Response to an HIV DNA Vaccine

D. Witten, D. Ho, R. Rabadán, 2008, PloS one.

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

D. Ho, L. Shapiro, P. Kwong, 2021, Cell Host & Microbe.

SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease

J. Sodroski, D. Ho, J. Yu, 2020, bioRxiv.

Extrapulmonary manifestations of COVID-19

H. Krumholz, D. Ho, G. Stone, 2020, Nature Medicine.

HIV-1 at 25

D. Ho, P. Bieniasz, David D. Ho, 2008, Cell.

Expression patterns of the HIV type 1 coreceptors CCR5 and CXCR4 on CD4+ T cells and monocytes from cord and adult blood.

J. Moore, D. Ho, J. Hoxie, 1998, AIDS research and human retroviruses.

Contribution of Human α-Defensin 1, 2, and 3 to the Anti-HIV-1 Activity of CD8 Antiviral Factor

E. Dalmasso, D. Ho, Linqi Zhang, 2002, Science.

Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor.

E. Dalmasso, D. Ho, Linqi Zhang, 2002, Science.

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization

D. Ho, J. Mascola, Yicheng Guo, 2021, bioRxiv.

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG

A. Trkola, C. Barbas, B. Korber, 1995, Journal of virology.

A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B

A. Trkola, B. Korber, J. Moore, 1995, Journal of virology.

HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells.

J. Moore, D. Ho, 1995, AIDS.

Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates

J. Moore, D. Ho, A. Ashkenazi, 1992, Journal of virology.

A case series of 104 women infected with HIV-1 via blood transfusion postnatally: high rate of HIV-1 transmission to infants through breast-feeding.

D. Ho, K. Liang, K. Zhuang, 2009, The Journal of infectious diseases.

Idiopathic CD4+ T-lymphocytopenia--immunodeficiency without evidence of HIV infection.

R. Schooley, D. Ho, Y. Cao, 1993, The New England journal of medicine.

Compartmentalization of Surface Envelope Glycoprotein of Human Immunodeficiency Virus Type 1 during Acute and Chronic Infection

D. Ho, M. Markowitz, Linqi Zhang, 2002, Journal of Virology.

for the origin of the epidemic

B. Korber, D. Ho, P. Sharp, 1998 .

Rapid-high, syncytium-inducing isolates of human immunodeficiency virus type 1 induce cytopathicity in the human thymus of the SCID-hu mouse

D. Ho, J. McCune, L. Su, 1994, Journal of virology.

Identification of a replication-competent pathogenic human immunodeficiency virus type 1 with a duplication in the TCF-1alpha region but lacking NF-kappaB binding sites

D. Ho, L. Zhang, B. K. Chen, 1997, Journal of virology.

Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy.

D. Ho, X. Jin, L. Zhang, 2000, The Journal of clinical investigation.

Characterization ofgagandpolSequences from Long-Term Survivors of Human Immunodeficiency Virus Type 1 Infection

D. Ho, Linqi Zhang, Yaoxing Huang, 1998 .

Genetic characterization of new West African simian immunodeficiency virus SIVsm: geographic clustering of household-derived SIV strains with human immunodeficiency virus type 2 subtypes and genetically diverse viruses from a single feral sooty mangabey troop

D. Ho, L. Zhang, A. Gettie, 1996, Journal of virology.

Viral Counts Count in HIV Infection

D. Ho, D D Ho, 1996, Science.

Biological characterization of nef in long-term survivors of human immunodeficiency virus type 1 infection

D. Ho, L. Zhang, Y. Huang, 1995, Journal of virology.

Characterization of nef sequences in long-term survivors of human immunodeficiency virus type 1 infection

D. Ho, L. Zhang, Y. Huang, 1995, Journal of virology.

Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase

A S Perelson, A. Perelson, D. Ho, 1996, Journal of virology.

Effect of recent thymic emigrants on progression of HIV-1 disease

Giota Touloumi, Cleo Anastassopoulou, Angelos Hatzakis, 2000, The Lancet.

The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses.

J. Moore, D. Ho, J. Binley, 1999, The Journal of infectious diseases.

Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase

D. Ho, P. Grob, J. Adams, 1997, Nature Medicine.

Perspectives Series: Host/Pathogen Interactions

D. Ho, 1997 .

DYNAMICS OF HIV-1 REPLICATION IN VIVO

D. Ho, 1997 .

Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins

R. Schooley, M. Hirsch, D. Ho, 1987, Journal of virology.

Longitudinal and cross-sectional analysis of cytotoxic T lymphocyte responses and their relationship to vertical human immunodeficiency virus transmission. ARIEL Project Investigators.

B. Walker, B. Korber, D. Ho, 1998, The Journal of infectious diseases.

Longitudinal and Cross-Sectional Analysis of Cytotoxic T Lymphocyte (CTL) Responses and their Relationship to Vertical HIV Transmission

B. Walker, B. Korber, D. Ho, 1998 .

Longitudinal and Cross-Sectional Analysis of Cytotoxic T Lymphocyte Responses and Their Relationship to Vertical Human Immunodeficiency Virus Transmission

B. Walker, B. Korber, D. Ho, 1998 .

Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals

D. Ho, Zhiwei Chen, K. Yuen, 2005, Journal of medical virology.

Single Amino Acid Substitutions in the Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Determine Viral Entry and Immunogenicity of a Major Neutralizing Domain

D. Ho, Zhiwei Chen, Linqi Zhang, 2005, Journal of Virology.

Recombinant Modified Vaccinia Virus Ankara Expressing the Spike Glycoprotein of Severe Acute Respiratory Syndrome Coronavirus Induces Protective Neutralizing Antibodies Primarily Targeting the Receptor Binding Region

D. Ho, Zhiwei Chen, K. Yuen, 2005, Journal of Virology.

Primary SIVsm isolates use the CCR5 coreceptor from sooty mangabeys naturally infected in west Africa: a comparison of coreceptor usage of primary SIVsm, HIV-2, and SIVmac.

D. Ho, Zhiwei Chen, A. Gettie, 1998, Virology.

SARS-CoV-2 hijacks neutralizing dimeric IgA for enhanced nasal infection and injury

D. Ho, K. To, J. Chan, 2021, bioRxiv.

Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development.

D. Ho, C. Rice, T. Moran, 2010, Vaccine.

Direct evidence for new T-cell generation by patients after either T-cell–depleted or unmodified allogeneic hematopoietic stem cell transplantationsPresented in part in abstract form at the 42nd Annual Meeting of the American Society of Hematology, San Francisco, CA, December 2000.

D. Ho, S. Lewin, Linqi Zhang, 2002 .

In Vivo Electroporation Enhances the Immunogenicity of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers

Jill Gilmour, Sandhya Vasan, D. Ho, 2011, PloS one.

Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report

D. Ho, T. Wrin, C. Petropoulos, 2005, The Lancet.

CD4+ lymphocytopenia in acute infection of Asian macaques by a vaginally transmissible subtype-C, CCR5-tropic Simian/Human Immunodeficiency Virus (SHIV).

D. Ho, Zhiwei Chen, A. Gettie, 2002, Journal of acquired immune deficiency syndromes.

Enhanced Infectivity of an R5-Tropic Simian/Human Immunodeficiency Virus Carrying Human Immunodeficiency Virus Type 1 Subtype C Envelope after Serial Passages in Pig-Tailed Macaques (Macaca nemestrina)

D. Ho, Zhiwei Chen, A. Gettie, 2000, Journal of Virology.

Chemokine Coreceptor Usage by Diverse Primary Isolates of Human Immunodeficiency Virus Type 1

J. Phair, D. Ho, Steven Wolinsky, 1998, Journal of Virology.

Evidence for coinfection by multiple strains of human immunodeficiency virus type 1 subtype B in an acute seroconvertor

D. Ho, Steven Wolinsky, A. Carr, 1995, Journal of virology.

Effect of different donor cells on human immunodeficiency virus type 1 replication and selection in vitro

D. Ho, A. Spira, 1995, Journal of virology.

Characterization of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte clones isolated during acute seroconversion: recognition of autologous virus sequences within a conserved immunodominant epitope

D. Ho, J. Safrit, R. Koup, 1994, The Journal of experimental medicine.

Increased Turnover of T Lymphocytes in HIV-1 Infection and Its Reduction by Antiretroviral Therapy

Alan S. Perelson, Ruy M. Ribeiro, L. Weinberger, 2001, The Journal of experimental medicine.

Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study

Hyeong Mi Kim, D. Ho, L. Stamatatos, 2021, Science.

Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor

D Norbeck, D. Ho, D. Norbeck, 1994, Journal of virology.

A Shot in the Arm for AIDS Vaccine Research

D. Ho, 2005, PLoS medicine.

Design, Construction, and Characterization of a Multigenic Modified Vaccinia Ankara Candidate Vaccine Against Human Immunodeficiency Virus Type 1 Subtype C/B′

D. Ho, Zhiwei Chen, Yaoxing Huang, 2008, Journal of Acquired Immune Deficiency Syndromes.

Human Immunodeficiency Virus Type 1 (HIV-1)-Specific CD8+-T-Cell Responses for Groups of HIV-1-Infected Individuals with Different HLA-B*35 Genotypes

J. Goedert, M. Carrington, S. O’Brien, 2002, Journal of Virology.

Neutralization Properties of Simian Immunodeficiency Viruses Infecting Chimpanzees and Gorillas

G. Learn, D. Ho, J. Mascola, 2015, mBio.

Genotyping HIV-1 and HCV Strains by a Combinatorial DNA Melting Assay (COMA)

Sunny Shin, D. Ho, L. Kostrikis, 1998, Molecular medicine.

Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4.

J. Moore, D. Ho, Y. Cao, 1993, AIDS research and human retroviruses.

Effects of in Vivo Cd8+ T Cell Depletion on Virus Replication in Rhesus Macaques Immunized with a Live, Attenuated Simian Immunodeficiency Virus Vaccine

A. Perelson, D. Ho, K. Metzner, 2000, The Journal of experimental medicine.

Characterization of gag and pol sequences from long-term survivors of human immunodeficiency virus type 1 infection.

D. Ho, L. Zhang, Y. Huang, 1998, Virology.

Decay Kinetics of Human Immunodeficiency Virus-Specific Effector Cytotoxic T Lymphocytes after Combination Antiretroviral Therapy

M. Nowak, D. Ho, Y. Cao, 1999, Journal of Virology.

Biological cloning of functionally diverse quasispecies of HIV-1.

D. Ho, Y. Cao, H. Mohri, 1993, AIDS research and human retroviruses.

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization

D. Ho, J. Mascola, Yicheng Guo, 2021, Research square.

Improved estimates for HIV-1 clearance rate and intracellular delay.

A S Perelson, A. Perelson, J. Mittler, 1999, AIDS.

Modeling Plasma Virus Concentration and CD4+ T Cell Kinetics during Primary HIV Infection

A. Perelson, D. Ho, L. Corey, 1999 .

Cryo-EM Structures Delineate a pH-Dependent Switch that Mediates Endosomal Positioning of SARS-CoV-2 Spike Receptor-Binding Domains

R. Friesner, D. Ho, J. Mascola, 2020, bioRxiv.

Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1

J. Moore, D. Ho, Y. Cao, 1994, Journal of virology.

In vivo replication kinetics of a nef-deleted strain of HIV-1.

D. Ho, B. Brew, J. Mills, 2005, AIDS.

Identification of Novel Small-Molecule Inhibitors of Severe Acute Respiratory Syndrome-Associated Coronavirus by Chemical Genetics

Herman Tse, Dan Yang, Kwok-Hung Chan, 2004, Chemistry & Biology.

Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1

J. Moore, D. Ho, J. Binley, 1997, Journal of virology.

Human immunodeficiency virus type 1 in a seronegative patient with visceral Kaposi's sarcoma and hypogammaglobulinemia.

D. Ho, B. Wallace, H. S. Robin, 1989, The American journal of medicine.

Dynamics of HIV-1 and CD4+ lymphocytes in vivo.

A S Perelson, A. Perelson, D. Ho, 1997, AIDS.

Acute fulminating fatal leukoencephalopathy as the only manifestation of human immunodeficiency virus infection

D. Ho, L. Adelman, M. Silverman, 1988, Annals of neurology.

Studies with monoclonal antibodies to the V3 region of HIV-1 gp120 reveal limitations to the utility of solid-phase peptide binding assays.

J. Moore, D. Ho, J. Robinson, 1994, Journal of acquired immune deficiency syndromes.

Human immunodeficiency virus type 1 induces persistent changes in mucosal and blood gammadelta T cells despite suppressive therapy.

D. Ho, A. Hurley, M. Markowitz, 2003, Journal of virology.

Markers of HIV infection prior to IgG antibody seropositivity.

D. Ho, J. Parry, R. Coombs, 1989, JAMA.

Infrequency of isolation of HTLV-III virus from saliva in AIDS.

R. Schooley, M. Hirsch, D. Ho, 1985, The New England journal of medicine.

Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4

D. Ho, Qiang Xu, G. Schoolnik, 2003, Proceedings of the National Academy of Sciences of the United States of America.

HIV-1 subtype and second-receptor use

D. Ho, Linqi Zhang, Yun-zhen Cao, 1996, Nature.

Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120

D. Ho, E. Daar, T. Chang, 1992, Journal of virology.

HTLV-III in the semen and blood of a healthy homosexual man.

R. Schooley, M. Hirsch, M. Gonda, 1984, Science.

African-American Infants Human Immunodeficiency Virus Type 1 to Influences Perinatal Transmission of of the CC-Chemokine Receptor 5 Gene A Polymorphism in the Regulatory Region

B. Korber, D. Ho, R. Koup, 2013 .

Detection of human anti‐HTLV‐III antibodies by indirect immunofluorescence using fixed cells

R. Schooley, M. Hirsch, D. Ho, 1985, Transfusion.

Absence of significant RNA-dependent DNA polymerase activity in lymphocytes from patients with Kawasaki syndrome

D. Ho, J. Kaplan, M. Melish, 1989, Nature.

Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region

J. Sodroski, D. Ho, J. Robinson, 1992, Journal of virology.

Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4

D. Ho, W. O'brien, E. Daar, 1992, Journal of virology.

Relative resistance of primary HIV-1 isolates to neutralization by soluble CD4.

D. Ho, E. Daar, 1991, The American journal of medicine.

Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody

D. Ho, J. Robinson, E. Daar, 1991, Journal of virology.

Cutaneous dendritic cells promote replication of immunodeficiency viruses.

R. Steinman, D. Ho, P. Marx, 1997, Advances in experimental medicine and biology.

DNA Vaccination by Electroporation Amplifies Broadly Cross-Restricted Public TCR Clonotypes Shared with HIV Controllers

D. Ho, S. Vasan, O. Lambotte, 2017, The Journal of Immunology.

Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti–HIV-1 IgG1 antibodies in vivo

A. Perelson, D. Ho, J. Yu, 2020, Proceedings of the National Academy of Sciences.

Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a Multigenic, DNA-Based Clade C/B' HIV-1 Candidate Vaccine

Yang Song, Soe Than, Martin Ho, 2010, PloS one.

Reactivity of E. coli-derived trans-activating protein of human T lymphotropic virus type III with sera from patients with acquired immune deficiency syndrome.

D. Ho, R. Gallo, F. Wong-Staal, 1986, Journal of immunology.

Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination.

A. Perelson, D. Ho, A. Hurley, 2002, The Journal of infectious diseases.

Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement

J. Moore, D. Ho, John P. Moore, 1996, Journal of virology.

Determining neutralization serotypes of HIV type 1 by neural networks.

J. Moore, D. Ho, Y. Cao, 1996, AIDS research and human retroviruses.

Temporal Analyses of Virus Replication, Immune Responses, and Efficacy in Rhesus Macaques Immunized with a Live, Attenuated Simian Immunodeficiency Virus Vaccine

D. Ho, J. Binley, John P. Moore, 1998, Journal of Virology.

HIV-1 Antigen–specific and –nonspecific B Cell Responses Are Sensitive to Combination Antiretroviral Therapy

D. Ho, J. Binley, John P. Moore, 1998, The Journal of experimental medicine.

Isolation of human immunodeficiency virus and detection of HIV DNA sequences in the brain of an ELISA antibody-negative child with acquired immune deficiency syndrome and progressive encephalopathy.

G. Shaw, D. Ho, M. Ragni, 1987, The Journal of pediatrics.

Safe disinfection of contact lenses after contamination with HTLV-III.

R. Schooley, M. Hirsch, D. Ho, 1986, Ophthalmology.

Quantitative Assays for Virus Detection

B. Walker, D. Ho, V. Johnson, 1990 .

In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: Why are CD4+ but not CD8+ T cells depleted?

Alan S. Perelson, Ruy M. Ribeiro, A. Perelson, 2002, Proceedings of the National Academy of Sciences of the United States of America.

The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy

Alan S. Perelson, John E. Mittler, Catherine A. Macken, 2000, Nature Medicine.

Different subtypes of HIV-1 and cutaneous dendritic cells.

D. Ho, M. Dittmar, J. Moore, 1997, Science.

Retraction of an Interpretation

D. Ho, Linqi Zhang, Wenjie Yu, 2004, Science.

Modeling deuterated glucose labeling of T-lymphocytes

Alan S. Perelson, Ruy M. Ribeiro, A. Perelson, 2002, Bulletin of mathematical biology.

The HIV-1 Vaccine Race

D. Ho, David D Ho, Yaoxing Huang, 2002, Cell.

Diverse Hepatitis C Virus Glycoproteins Mediate Viral Infection in a CD81-Dependent Manner

D. Ho, C. Rice, L. Zhang, 2004, Journal of Virology.

Functional interaction and partial homology between human immunodeficiency virus and neuroleukin.

M. Gurney, D. Ho, Mark Lee, 1987, Science.

The influence of proline isomerization on potency and stability of anti-HIV antibody 10E8

Brian D. Weitzner, D. Ho, J. Yu, 2020, Scientific Reports.

Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody.

Michael S Seaman, Bing Chen, D. Ho, 2010, Structure.

Evidence of two distinct subsubtypes within the HIV-1 subtype A radiation.

D. Ho, D. Robertson, L. Kostrikis, 2001, AIDS research and human retroviruses.

Genetic analysis of human immunodeficiency virus type 1 strains from patients in Cyprus: identification of a new subtype designated subtype I

D. Ho, Y. Cao, L. Zhang, 1995, Journal of virology.

Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles

Daniel S. Terry, D. Ho, J. Mascola, 2020, bioRxiv.

Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles

Daniel S. Terry, D. Ho, J. Mascola, 2020, Cell Host & Microbe.

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo

Serena Xu, Anandan Palani, William J. Greenlee, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies

D. Ho, Yicheng Guo, Z. Sheng, 2021, Structure.

Structural Basis for Accommodation of Emerging B.1.351 and B.1.1.7 Variants by Two Potent SARS-CoV-2 Neutralizing Antibodies

D. Ho, Yicheng Guo, J. Yu, 2021, bioRxiv.

Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates

D. Ho, Gregory D. Gromowski, M. Diamond, 2021, bioRxiv.

Immunogenicity and protective efficacy of recombinant Clostridium difficile flagellar protein FliC

D. Ho, Xingmin Sun, Adrianne N. Edwards, 2016, Emerging Microbes & Infections.

Spectral Genotyping of Human Alleles

Fred Russell Kramer, Sanjay Tyagi, Sanjay Tyagi, 1998, Science.

Safety and Immunogenicity of ALVAC vCP1452 and Recombinant gp160 in Newly Human Immunodeficiency Virus Type 1-Infected Patients Treated with Prolonged Highly Active Antiretroviral Therapy

D. Ho, J. Binley, A. Hurley, 2002, Journal of Virology.

Highly Active Antiretroviral Therapy 1-Infected Patients Treated with Prolonged Human Immunodeficiency Virus Type vCP 1452 and Recombinant gp 160 in Newly Safety and Immunogenicity of ALVAC

D. Ho, J. Binley, A. Hurley, 2002 .

Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants

D. Ho, M. Nussenzweig, P. Bieniasz, 2021, Nature.

Andrews 1..9

D. Ho, C. Cheng‐Mayer, M. Markowitz, 2015 .

Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor

D. Ho, T. Bhat, M. Markowitz, 1995, Journal of virology.

Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy.

D. Ho, C. Petropoulos, M. Markowitz, 1999, The Journal of infectious diseases.

To Promote Circumcision as a Preventive Measure against Human Immunodeficiency Virus Transmission Is Irresponsible

D. Ho, C. Petropoulos, M. Markowitz, 2010 .

Broadly neutralizing DNA vaccine with specific mutation alters the antigenicity and sugar-binding activities of influenza hemagglutinin

D. Ho, Chi‐Huey Wong, Chung-Yi Wu, 2011, Proceedings of the National Academy of Sciences.

Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes

D. Ho, J. Mascola, N. Sullivan, 2020, Cell Reports.

Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes.

D. Ho, J. Mascola, N. Sullivan, 2020, SSRN.

Experimental infection with Haemophilus ducreyi in persons who are infected with HIV does not cause local or augment systemic viral replication.

D. Ho, P. Rácz, K. Fortney, 2007, The Journal of infectious diseases.

Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques

Alan S. Perelson, A. Perelson, D. Ho, 2007, Proceedings of the National Academy of Sciences.

Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody

J. Sodroski, D. Ho, N. Sullivan, 1993, Journal of virology.

Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies

D. Ho, K. To, J. Chan, 2021, Cell Host & Microbe.

Antibody-dependent cell-mediated cytotoxicity against cells infected with the human immunodeficiency virus.

R. Schooley, M. Hirsch, D. Ho, 1987, The Journal of infectious diseases.

Antibody to lymphadenopathy-associated virus in AIDS.

M. Hirsch, D. Ho, T. Rota, 1985, The New England journal of medicine.

Cardiomyocytes recruit monocytes upon SARS-CoV-2 infection by secreting CCL2

A. Borczuk, D. Ho, R. Schwartz, 2021, Stem Cell Reports.

Rapid turnover of T lymphocytes in SIV-infected rhesus macaques.

A S Perelson, S Bonhoeffer, A. Perelson, 1998, Science.

Molecular tracking of an Human Immunodeficiency Virus nef specific cytotoxic T-cell clone shows persistence of clone-specific T-cell receptor DNA but not mRNA following early combination antiretroviral therapy.

D. Ho, Y. Cao, D. Nixon, 1999, Immunology letters.

In Vivo Distribution of the Human Immunodeficiency Virus/Simian Immunodeficiency Virus Coreceptors: CXCR4, CCR3, and CCR5

D. Ho, Linqi Zhang, A. Talal, 2001, Journal of Virology.

Engineering multi-specific antibodies against HIV-1

D. Ho, Neal N. Padte, Yaoxing Huang, 2018, Retrovirology.

Genetic characterization of vif, vpr, and vpu sequences from long-term survivors of human immunodeficiency virus type 1 infection.

D. Ho, L. Zhang, S. Tuttleton, 1997, Virology.

Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors

Seo Jung Hong, D. Ho, B. Stockwell, 2021, Nature Communications.

Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors

Seo Jung Hong, D. Ho, B. Stockwell, 2020, bioRxiv.

Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients.

D. Ho, H. Mohri, M. Singh, 1993, Proceedings of the National Academy of Sciences of the United States of America.

HIV type 1 subtypes, coreceptor usage, and CCR5 polymorphism.

D. Ho, L. Zhang, B. Hahn, 1997, AIDS research and human retroviruses.

Perspectives series: host/pathogen interactions. Dynamics of HIV-1 replication in vivo.

D. Ho, D D Ho, 1997, The Journal of clinical investigation.

Toward HIV eradication or remission: the tasks ahead.

D. Ho, D D Ho, D. Ho, 1998, Science.

Characterization of the functional properties of env genes from long-term survivors of human immunodeficiency virus type 1 infection

D. Ho, L. Zhang, R. Connor, 1996, Journal of virology.

Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off

D R Burton, C. Barbas, J. Moore, 1997, Journal of virology.

In vivo expressed biologics for infectious disease prophylaxis: rapid delivery of DNA-based antiviral antibodies

D. Ho, Yaoxing Huang, Rachel A. Liberatore, 2020, Emerging microbes & infections.

In Vivo Production of Monoclonal Antibodies by Gene Transfer via Electroporation Protects against Lethal Influenza and Ebola Infections

D. Ho, Pamela J. Glass, Neal N. Padte, 2017, Molecular therapy. Methods & clinical development.

Peripheral neuropathy in the acquired immunodeficiency syndrome

R. Schooley, M. Hirsch, D. Ho, 1988, Annals of neurology.

Viral Blip Dynamics during Highly Active Antiretroviral Therapy

Alan S. Perelson, Christine Hogan, A. Perelson, 2003, Journal of Virology.

Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies

J. Moore, D. Ho, J. Mascola, 1994, Journal of virology.

DNA-immunization with a V2 deleted HIV-1 envelope elicits protective antibodies in macaques.

D. Ho, L. Stamatatos, X. Jin, 2001, Immunology letters.

DNA Vaccination with the Human Immunodeficiency Virus Type 1 SF162ΔV2 Envelope Elicits Immune Responses That Offer Partial Protection from Simian/Human Immunodeficiency Virus Infection to CD8+ T-Cell-Depleted Rhesus Macaques

D. Ho, L. Stamatatos, X. Jin, 2001, Journal of Virology.

Virus-Like Particle Based-Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide

D. Ho, J. Mascola, P. Kwong, 2020 .

Primary HIV-1 infection.

S. J. Clark, D. Ho, J. Levy, 1991, The New England journal of medicine.

CRISPR-based gene knockout screens reveal deubiquitinases involved in HIV-1 latency in two Jurkat cell models

D. Ho, A. Rathore, M. Jia, 2020, Scientific Reports.

Characterization of mutants of human immunodeficiency virus type 1 that have escaped neutralization by a monoclonal antibody to the gp120 V2 loop

J. Moore, H. Yoshiyama, D. Ho, 1994, Journal of virology.

Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody.

D. Ho, T. Chang, M. Fung, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Turnover Rates of B Cells, T Cells, and NK Cells in Simian Immunodeficiency Virus-Infected and Uninfected Rhesus Macaques1

Alan S. Perelson, A. Perelson, D. Ho, 2003, The Journal of Immunology.

Shutting down HIV

D. Ho, R. Koup, Richard A. Koup, 1994, Nature.

Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein.

J. Sodroski, D. Ho, J. Robinson, 1992, Journal of acquired immune deficiency syndromes.

Genotypic and phenotypic characterization of long terminal repeat sequences from long-term survivors of human immunodeficiency virus type 1 infection

D. Ho, L. Zhang, Linqi Zhang, 1997, Journal of virology.

Relationship between acute myelomonoblastic leukemia and infection due to human immunodeficiency virus.

D. Ho, M. Goetz, A. R. Murthy, 1991, Reviews of infectious diseases.

Persistent Antibody Responses but Declining Cytotoxic T-Lymphocyte Responses to Multiple Human Immunodeficiency Virus Type 1 Antigens in a Long-Term Nonprogressing Individual with a Defective p17 Proviral Sequence and No Detectable Viral RNA Expression

D. Ho, J. Binley, John P. Moore, 1998, Journal of Virology.

Intensification of Antiretroviral Therapy Accelerates the Decay of the HIV-1 Latent Reservoir and Decreases, But Does Not Eliminate, Ongoing Virus Replication

Alan S Perelson, A. Perelson, D. Ho, 2004, Journal of acquired immune deficiency syndromes.

Seroreactivity of analogous antigenic epitopes in glycoprotein 120 expressed in HIV-1 subtypes A, B, C, and D.

D. Ho, N. Sewankambo, L. Brown, 1995, AIDS research and human retroviruses.

Identification of a protein encoded by the trans activator gene tatIII of human T-cell lymphotropic retrovirus type III

J. Sodroski, D. Ho, W. Haseltine, 1986, Journal of virology.

Macaques Virus-Infected and Uninfected Rhesus Cells in Simian Immunodeficiency Turnover Rates of B Cells , T Cells , and NK

A. Perelson, D. Ho, R. J. Boer, 2003 .

Impact of thymectomy on the peripheral T cell pool in rhesus macaques before and after infection with simian immunodeficiency virus

Ruy M Ribeiro, Alan S Perelson, James Blanchard, 2005, European journal of immunology.

Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity.

D. Ho, S. Marsters, A. Ashkenazi, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Sequential changes in antibody levels to the ENV and GAG Antigens in human immunodeficiency virus infected subjects

D. Ho, R. Gallo, N. Manca, 1987, European Journal of Epidemiology.

IN HUIMAN IMMUNODEFICIENCY VIRUS INFECTED SUBJECTS

D. Ho, N. Manca, 2016 .

The Miami Monkey: A Sunny Alternative to the Berlin Patient.

D. Ho, Rachel A. Liberatore, 2019, Immunity.

Immunosilent HIV-1 infection: intrigue continues.

D. Ho, R. Koup, 1991, AIDS.

Open-label phase II trial of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine in newly and chronically HIV-1--infected patients.

D. Ho, S. Furlan, A. Hurley, 2001 .

HIV-1 rebound after anti-retroviral therapy

D. Ho, Linqi Zhang, 2000, Nature Medicine.

Was HIV present in 1959?

D. Ho, Tuofu Zhu, 1995, Nature.

A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection.

D. Ho, A. Hurley, M. Markowitz, 1995, The New England journal of medicine.

Engineering multi-specific antibodies against HIV-1

D. Ho, Neal N. Padte, Yaoxing Huang, 2018, Retrovirology.

Design, synthesis, and resistance patterns of MP-134 and MP-167, two novel inhibitors of HIV type 1 protease.

D. Ho, M. Markowitz, S. Gulnik, 1996, AIDS research and human retroviruses.

Isolation and characterization of the first simian immunodeficiency virus from a feral sooty mangabey (Cercocebus atys) in West Africa

D. Ho, Linqi Zhang, P. Marx, 1995 .

CRISPR-based gene knockout screens reveal deubiquitinases involved in HIV-1 latency in two Jurkat cell models

D. Ho, A. Rathore, M. Jia, 2020, Scientific Reports.

Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques

D. Ho, Gregory D. Gromowski, M. Diamond, 2021, Proceedings of the National Academy of Sciences.

Estimates of Intracellular Delay and Average Drug Efficacy from Viral Load Data of HIV-Infected Individuals under Antiretroviral Therapy

Alan S Perelson, A. Perelson, D. Ho, 2004, Antiviral therapy.

Improving Mycobacterium bovis Bacillus Calmette-Guèrin as a Vaccine Delivery Vector for Viral Antigens by Incorporation of Glycolipid Activators of NKT Cells

B. Haynes, D. Ho, G. Besra, 2014, PLoS ONE.

Cellular targets of infection and route of viral dissemination following an intravaginal inoculation of SIV into rhesus macaques

D. Ho, Steven Wolinsky, R. Koup, 1998 .

Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody.

D. Ho, Bing Chen, M. Seaman, 2010, Structure.

A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A.

D. Ho, D. Franco, D. Gardiner, 2009, Vaccine.

SARS-CoV-2 viral dynamics in acute infections

D. Ho, S. Kissler, C. Mack, 2020 .

IMMUNOHISTOCHEMICAL IDENTIFICATION OF HTLV-III ANTIGEN IN BRAIN FROM PATIENTS WITH THE SUBACUTE ENCEPHALITIS (SE) OF THE ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)

D. Ho, R. Sobel, D. Gabuzda, 1986 .

Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses

Paul J. Steiner, Timothy A. Whitehead, D. Ho, 2021, Cell Reports.

Characterization of long-term survivors of human immunodeficiency virus type 1 infection.

D. Ho, L. Zhang, J. Safrit, 1996, Immunology letters.

Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain

D. Ho, Yicheng Guo, Z. Sheng, 2021, Cell Reports.

Identification of Novel Small-Molecule Inhibitors of Severe Acute Respiratory Syndrome-Associated Coronavirus by Chemical Genetics

Guanhua Chen, D. Ho, Kwok-Hung Chan, 2004, Chemistry & Biology.

Intermittent shedding of human immunodeficiency virus in semen: implications for sexual transmission.

J. Zeh, D. Ho, A. Collier, 1995, The Journal of urology.

Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a Multigenic, DNA-Based Clade C/B' HIV-1 Candidate Vaccine

D. Ho, Zhiwei Chen, A. Hurley, 2010, PloS one.

Extrapulmonary manifestations of COVID-19

H. Krumholz, D. Ho, G. Stone, 2020, Nature Medicine.